Patients with myelodysplastic syndromes treated with azacitidine in clinical practice: the AVIDA<sup>®</sup>registryDavid L. Grinblatt, Mohit Narang, Mikkael A. Sekeres et al.|Leukemia & lymphoma/Leukemia and lymphoma|2014Cited by 40
A Study Comparing Dosing Regimens and Efficacy of Subcutaneous to Intravenous Azacitidine (AZA) for the Treatment of Myelodysplastic Syndromes (MDS).Mikkael A. Sekeres, Kristen Sullivan, Jaroslaw P. Maciejewski et al.|Blood|2009Cited by 15
Treatment of Patients with Low-Risk Myelodysplastic Syndromes Receiving Azacitidine Who Are Enrolled in AVIDA, a Longitudinal Patient Registry.David L. Grinblatt, Kristen Sullivan, Mohit Narang et al.|Blood|2008Cited by 8
Therapeutic Response to Azacitidine (AZA) In Patients with Secondary Myelodysplastic Syndromes (sMDS) Enrolled In the AVIDA RegistryMikkael A. Sekeres, David L. Grinblatt, Kristen Sullivan et al.|Blood|2010Cited by 5
Early mortality (EM) for newly diagnosed multiple myeloma (NDMM) in the Connect MM U.S. registry.Howard R. Terebelo, Robert M. Rifkin, Jatin J. Shah et al.|Journal of Clinical Oncology|2013Cited by 3